Central European Early Bronze Age chronology revisited: A Bayesian examination of large-scale radiocarbon dating

In archaeological research, changes in material culture and the evolution of styles are taken as major indicators for socio-cultural transformation. They form the basis for typo-chronological classification and the establishment of phases and periods. Central European Bronze Age material culture from burials reveals changes during the Bronze Age and represents a perfect case study for analyzing phenomena of cultural change and the adoption of innovation in the societies of prehistoric Europe. Our study focuses on the large-scale change in material culture which took place in the second millennium BC and the emergence at the same period of new burial rites: the shift from inhumation burials in flat graves to complex mounds and simple cremation burials. Paul Reinecke was the first to divide the European Bronze Age (EBA) into two phases, Bz A1 and A2. The shift from the first to the second phase has so far been ascribed to technical advances. Our study adopted an innovative approach to quantifying this phenomenon. Through regressive reciprocal averaging and Bayesian analysis of radiocarbon-dated grave contexts located in Switzerland and southern Germany, we modelled chronological changes in the material culture and changes in burial rites in these regions in a probabilistic way. We used kernel density models to summarize radiocarbon dates, with the aim of visualizing cultural changes in the third and second millennium BC. In 2015, Stockhammer et al. cast doubt on the chronological sequence of the Reinecke phases of the EBA on the basis of newly collected radiocarbon dates from southern Germany. Our intervention is a direct response to the results of that study. We fully agree with Stockhammer’s et al. dating of the start of EBA, but propose a markedly different dating of the EBA/MBA transition. Our modelling of radiocarbon data demonstrates a statistically significant typological sequence of phases Bz A1, Bz A2 and Bz B and disproves their postulated chronological overlap. The linking of the archaeological relative-chronological system with absolute dates is of major importance to understanding the temporal dimension of the EBA phases

Central European Early Bronze Age chronology revisited: A Bayesian examination of large-scale radiocarbon dating

In archaeological research, changes in material culture and the evolution of styles are taken as major indicators for socio-cultural transformation. They form the basis for typo-chronological classification and the establishment of phases and periods. Central European Bronze Age material culture from burials reveals changes during the Bronze Age and represents a perfect case study for analyzing phenomena of cultural change and the adoption of innovation in the societies of prehistoric Europe. Our study focuses on the large-scale change in material culture which took place in the second millennium BC and the emergence at the same period of new burial rites: the shift from inhumation burials in flat graves to complex mounds and simple cremation burials. Paul Reinecke was the first to divide the European Bronze Age (EBA) into two phases, Bz A1 and A2. The shift from the first to the second phase has so far been ascribed to technical advances. Our study adopted an innovative approach to quantifying this phenomenon. Through regressive reciprocal averaging and Bayesian analysis of radiocarbon-dated grave contexts located in Switzerland and southern Germany, we modelled chronological changes in the material culture and changes in burial rites in these regions in a probabilistic way. We used kernel density models to summarize radiocarbon dates, with the aim of visualizing cultural changes in the third and second millennium BC. In 2015, Stockhammer et al. cast doubt on the chronological sequence of the Reinecke phases of the EBA on the basis of newly collected radiocarbon dates from southern Germany. Our intervention is a direct response to the results of that study. We fully agree with Stockhammer’s et al. dating of the start of EBA, but propose a markedly different dating of the EBA/MBA transition. Our modelling of radiocarbon data demonstrates a statistically significant typological sequence of phases Bz A1, Bz A2 and Bz B and disproves their postulated chronological overlap. The linking of the archaeological relative-chronological system with absolute dates is of major importance to understanding the temporal dimension of the EBA phases

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit